Competitor Analysis: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
The Competitive Intelligence Report Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists as of August 2014 provides a competitor analysis in the development pipeline of novel GLP-1 analogs and GLP-1 receptor agonists and co-agonists for treatment of diabetes and obesity.
In the year 2013, the marketed daily and weekly GLP-1 agonists achieved combined sales of US$ 3,231 mln representing 6.3% of the total diabetes care market. The leading GLP-1 analog Victoza held 69% of the GLP-1 market and is further expanding its predominance in the first half of 2014 with a 72% share of the GLP-1 market which grew to 6.9% of the total diabetes care market.
The increasingly attractive GLP-1 market provides an opportunity of application of new technologies to prolong the half-life of GLP-1 analogs as well as finding co-agonists of GLP-1 receptor with additional receptors, such as insulin, glucagon, GIP, gastrin or GLP-1. In addition, expansion of indications for GLP-1 analogs will contribute to further expand the GLP-1 market.
The report provides a compilation of current active projects in research and development of novel GLP-1 analogs and GLP-1 receptor agonists as well as co-agonists. Competitor projects are listed in a tabular format providing information on:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
The Competitive Intelligence Report Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists as of August 2014 provides a competitor analysis in the development pipeline of novel GLP-1 analogs and GLP-1 receptor agonists and co-agonists for treatment of diabetes and obesity.
In the year 2013, the marketed daily and weekly GLP-1 agonists achieved combined sales of US$ 3,231 mln representing 6.3% of the total diabetes care market. The leading GLP-1 analog Victoza held 69% of the GLP-1 market and is further expanding its predominance in the first half of 2014 with a 72% share of the GLP-1 market which grew to 6.9% of the total diabetes care market.
The increasingly attractive GLP-1 market provides an opportunity of application of new technologies to prolong the half-life of GLP-1 analogs as well as finding co-agonists of GLP-1 receptor with additional receptors, such as insulin, glucagon, GIP, gastrin or GLP-1. In addition, expansion of indications for GLP-1 analogs will contribute to further expand the GLP-1 market.
The report provides a compilation of current active projects in research and development of novel GLP-1 analogs and GLP-1 receptor agonists as well as co-agonists. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
1. SELECTIVE GLP-1 ANALOGS FOR METABOLIC DISEASES
2013 SALES OF GLP-1 ANALOGS
Short-Acting Injectable GLP-1 Analogs
Long-Acting Injectable GLP-1 Analogs
Very Long-Acting Injectable GLP-1 Analogs
Oral Peptide-Based GLP-1 Analogs
Other Non-Injectable Peptide-Based GLP-1 Analogs
Oral Small Molecule GLP-1 Receptor Agonists
2. SELECTIVE GLP-1 ANALOGS FOR NON-METABOLIC DISEASES
3. DUAL TARGET GLP-1 ANALOGS
GLP-1 and Insulin
GLP-1 and Glucagon
GLP-1 and GIP
GLP-1 and Gastrin/CCKB
GLP-1 and GLP-2
4. CORPORATE GLP-1 RECEPTOR AGONIST R&D PIPELINES
2013 SALES OF GLP-1 ANALOGS
Short-Acting Injectable GLP-1 Analogs
Long-Acting Injectable GLP-1 Analogs
Very Long-Acting Injectable GLP-1 Analogs
Oral Peptide-Based GLP-1 Analogs
Other Non-Injectable Peptide-Based GLP-1 Analogs
Oral Small Molecule GLP-1 Receptor Agonists
2. SELECTIVE GLP-1 ANALOGS FOR NON-METABOLIC DISEASES
3. DUAL TARGET GLP-1 ANALOGS
GLP-1 and Insulin
GLP-1 and Glucagon
GLP-1 and GIP
GLP-1 and Gastrin/CCKB
GLP-1 and GLP-2
4. CORPORATE GLP-1 RECEPTOR AGONIST R&D PIPELINES
